133041-90-4

Basic information

• Product Name: 4-(QUINOLIN-4-YLAMINO)-BENZOIC ACID
• Synonyms: 4-(QUINOLIN-4-YLAMINO)-BENZOIC ACID
• CAS NO: 133041-90-4
• Molecular Formula: C₁₆H₁₂N₂O₂
• Molecular Weight: 264.28
• Mol File: 133041-90-4.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(QUINOLIN-4-YLAMINO)-BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(QUINOLIN-4-YLAMINO)-BENZOIC ACID(133041-90-4)
• EPA Substance Registry System: 4-(QUINOLIN-4-YLAMINO)-BENZOIC ACID(133041-90-4)

Safety Data

• Hazardous Substances Data: 133041-90-4(Hazardous Substances Data)

Upstream product

• 58519-43-0 ethyl 4-((quinolin-4-yl)amino)benzoate 
• 94-09-7 p-aminoethylbenzoate 
• 611-35-8 4-chloroquinoline 
• 150-13-0 4-amino-benzoic acid 

Downstream Products

• 1020149-73-8 N-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-4-(4-quinolinylamino)benzamide 
• 1535187-97-3 N-(4-aminophenyl)-4-(quinolin-4-ylamino)benzamide 
• 1020087-27-7 N-(3-(2-amino-6-methylpyrimidin-4-ylamino)phenyl)-4-(quinolin-4-ylamino)benzamide 
• 1535187-89-3 N-(2-(2-amino-6-methylpyrimidin-4-ylamino)phenyl)-4-(quinolin-4-ylamino)benzamide 
• 218629-10-8 diethyl 2-(methylthio)-1-<3-<4-<4-(4-quinolinylamino)benzamido>phenyl>propyl>imidazole-4,5-dicarboxylate 
• 218629-12-0 N-{4-[3-(4,5-bis-hydroxymethyl-2-methylsulfanyl-imidazol-1-yl)-propyl]-phenyl}-4-(quinolin-4-ylamino)-benzamide 
• 218629-09-5 dimethyl 1-<3-<4-<4-(4-quinolinylamino)benzamido>phenyl>propyl>imidazole-4,5-dicarboxylate 
• 218629-11-9 N-{4-[3-(4,5-bis-hydroxymethyl-imidazol-1-yl)-propyl]-phenyl}-4-(quinolin-4-ylamino)-benzamide 

Relevant articles and documents

Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells

DNA methyltransferases (DNMTs) are important enzymes involved in epigenetic control of gene expression and represent valuable targets in cancer chemotherapy. A number of nucleoside DNMT inhibitors (DNMTi) have been studied in cancer, including in cancer stem cells, and two of them (azacytidine and decitabine) have been approved for treatment of myelodysplastic syndromes. However, only a few non-nucleoside DNMTi have been identified so far, and even fewer have been validated in cancer. Through a process of hit-to-lead optimization, we report here the discovery of compound 5 as a potent non-nucleoside DNMTi that is also selective toward other AdoMet-dependent protein methyltransferases. Compound 5 was potent at single-digit micromolar concentrations against a panel of cancer cells and was less toxic in peripheral blood mononuclear cells than two other compounds tested. In mouse medulloblastoma stem cells, 5 inhibited cell growth, whereas related compound 2 showed high cell differentiation. To the best of our knowledge, 2 and 5 are the first non-nucleoside DNMTi tested in a cancer stem cell line.

Some derivatives of p-aminobenzoic acid.

-